で公開中です！ 詳しく見る
MRNAのアイコン

Moderna
MRNA

218.01 USD
-18.49
7.82%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
215.80
-2.21
1.01%
1日
-7.82%
5日間
-2.89%
1か月
49.71%
3か月
245.23%
6か月
298.7%
年初来
606.45%
1年
703.28%
5年間
-34.89%
10年間
1,072.1%
 

概要： Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

従業員数： 4,700

ヘルスケア バイオテクノロジー

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 57.5%
ニュートラル 25.7%
ネガティブ 16.9%
ネガティブ
Barrons
6 時間前
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
ネガティブ
Invezz
8 時間前
Why is Moderna down 10% on Friday?
Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the biotechnology to its 52-week high. The shares, which reached $242.29 during their recent advance, were trading near $213 at the time of writing.
Why is Moderna down 10% on Friday?
ネガティブ
24/7 Wall Street
9 時間前
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
ネガティブ
24/7 Wall Street
11 時間前
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
ポジティブ
The Motley Fool
15 時間前
Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
AI stocks have been known for explosive gains in recent years and have driven the S&P 500 higher. This year, some investors scored a much bigger win by investing in a promising biotech stock.
Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
ニュートラル
Seeking Alpha
昨日
Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain
Moderna has staged a dramatic rebound, becoming the best-performing S&P 500 stock YTD, driven by pipeline optimism and strong technical momentum. I maintain a "Hold" rating on MRNA due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on pipeline execution. Key catalysts include upcoming Q3 earnings on November 6 and Analyst Day on November 12, with high implied volatility and significant event-driven price risk.
Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain
ポジティブ
Benzinga
昨日
Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks
Shares of Nike Inc. (NYSE:NKE), Moderna Inc. (NASDAQ:MRNA) and Walmart Inc. (NASDAQ:WMT) climbed Thursday as money flowed out of tech and AI stocks for a second straight session.
Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks
ポジティブ
24/7 Wall Street
昨日
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
ニュートラル
Bloomberg Markets and Finance
昨日
Moderna, Google DeepMind, Biocon on AI in Science
Noubar Afeyan, Co-Founder & Chairman, Moderna and Founder & CEO, Flagship Pioneering; Lila Ibrahim, Chief AI Readiness Officer, Google DeepMind; and Kiran Mazumdar-Shaw, Founder & Executive Chairperson, Biocon discuss how AI is reshaping scientific discovery with Bloomberg's Francine Lacqua at the 2026 Bloomberg New Economy Forum in New Delhi. -------- More on Bloomberg Television and Markets Like this video?
Moderna, Google DeepMind, Biocon on AI in Science
ニュートラル
24/7 Wall Street
昨日
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています